Cytosorbents Corporation is a critical care company specializing in blood purification technologies for the treatment of life-threatening conditions in intensive care units and cardiac surgery. The company develops proprietary, biocompatible, highly porous polymer beads that remove toxic substances from blood and bodily fluids through pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge approved in the European Union and distributed internationally, used to reduce cytokine storms, remove bilirubin and myoglobin, and manage antithrombotic drugs during cardiothoracic procedures. The company also commercializes ECOS-300CY for ex vivo organ perfusion in transplant settings and VetResQ for emergency and critical care in animals, primarily in the United States. Additionally, Cytosorbents develops the DrugSorb-ATR antithrombotic removal system, an investigational device designed to reduce perioperative bleeding in high-risk surgery by removing blood thinners such as ticagrelor and rivaroxaban. The company also commercializes the PuriFi hemoperfusion pump in select international markets. Cytosorbents serves healthcare professionals and hospitals globally, with a focus on critical care, cardiac surgery, and veterinary medicine.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage cytosorbents.com
Sector Healthcare IR page ir.cytosorbents.com
Tags
blood purification, hemoadsorption, critical care, cardiac surgery, cytokine removal, antithrombotic reversal, organ perfusion, veterinary medicine, polymer beads, extracorporeal therapy, CytoSorb, DrugSorb-ATR, ECOS-300CY, VetResQ, PuriFi
Press page ir.cytosorbents.com/pressrelease

Metrics

Valuation  
Market cap $ 245.087M
Market cap (USD) $ 245.087M
P/E -13.45
PEG —
P/BV -326.35
P/S 6.59
P/OCF -26.79
P/FCF -26.36
Dividend yield —
Turnover / mcap —
Returns  
ROE -96.4%
ROI -36.3%
ROIC -49.0%
Profit margin -22.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 37.063M 35.595M 36.349M 34.689M 43.166M 41.005M 24.949M 20.252M 15.151M 9.528M 4.792M 4.123M 2.423M 1.343M 36.078K — — —
Net profit -8.198M -20.719M -28.507M -32.813M -24.559M -7.837M -19.266M -17.211M -8.461M -11.939M -8.132M -9.322M -4.678M -3.664M -5.482M -2.909M — —
Free cash flow -12.541M -14.712M -22.193M -34.322M -17.647M -6.322M -17.457M -11.512M -7.451M -6.872M -9.413M -6.814M -3.528M -3.636M -3.863M -2.617M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 0.64 0.91 1.11 1.55 4.19 7.97 3.85 8.08 6.5 5.45 5.57 9.94 — 0.13 0.27 — — —
Price performance 12m -0.3 -0.18 -0.28 -0.63 -0.47 1.07 -0.52 0.24 0.19 -0.02 -0.44 — — -0.52 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.43M 2.21M 3.94M 4.47M 5.16M 4.52M 5.66M 6.06M 7.32M 7.55M
↳ YoY growth +120.9% +53.9% +78.8% +13.3% +15.5% -12.3% +25.2% +6.9% +20.8% +3.1%
↳ 5y CAGR +108.8% +40.4% +51.4% +25.8% +20.8% +9.0% +10.4% +7.9%
Borrowings, current (USD) 833,333 4M 666,667 1.67M 0.00 — — 2.5M — —
Borrowings, non-current (USD) 4.08M 5.99M 9.27M 13.4M 0.00 — 5M 2.54M 14M 16.7M
Lease liabilities (USD) — — 1.45M 1.07M 1.03M 13.8M 13.3M 13.3M 12.9M 12.4M
Cash and deposits (USD) 5.25M 17.3M 22.4M 12.2M 71.4M 52.1M 22.1M 14.1M 3.28M 6.25M
Intangible assets (USD) — 1.84M 2.63M 3.36M 4.22M 4.7M 4.39M 3.91M 3.75M 3.23M
Right-of-use assets (USD) — — 1.45M 1.07M 1.03M 13.4M 12.6M 12.1M 11.5M 10.9M
Net debt (borrowings + leases - cash) (USD) -333,531 -7.33M -12.4M 3.89M -70.4M — -3.89M 4.18M 23.6M 22.9M
Cash flow detail
Operating cash flow (USD) -6.73M -6.46M -10.8M -16.8M -5.61M -14M -28.2M -21.7M -14.4M -12.4M
Purchases of property, plant and equipment (USD) -140,724 -990,673 -671,970 -698,165 -708,395 -3.64M -6.09M -538,115 -284,343 -164,000
Purchases of intangible assets (USD) -454,807 -687,446 -848,294 -821,952 -967,823 -640,013 -368,211 -398,121 -385,087 -327,000
Change in receivables (cash effect) (USD) -889,715 -649,318 -1.85M -642,171 -326,860 420,578 -1.29M -245,616 -1.72M 423,000
Change in inventories (cash effect) (USD) 340,392 57,320 -56,751 -1.28M -461,512 -2.35M 945,352 -121,039 500,466 -2.54M
Change in payables (cash effect) (USD) 2.06M 523,377 1.7M 1.42M 1.11M 2.43M -3.25M 1.62M -1.81M -706,000
Interest paid (cash effect) (USD) -175,897 -634,608 -891,386 -1.06M -1.13M — — -376,668 -1.29M -2.08M
Income taxes paid (cash effect) (USD) — — — — — — — — 881,000 1.71M
Share-based compensation (USD) 2.76M 3.31M 4.44M 1.67M 3.51M 4.02M 3.42M 3.33M 3.76M 2.77M
Operating cash flow before change in receivables (USD) -5.84M -5.81M -8.99M -16.1M -5.29M -14.4M -26.9M -21.4M -12.7M -12.8M
Free cash flow (OCF - PPE - intangibles) (USD) -7.33M -8.14M -12.4M -18.3M -7.29M -18.3M -34.7M -22.6M -15.1M -12.9M
Income detail
Research and development expense (USD) 4.78M 4.05M 7.72M 12.1M 8.81M 16.4M 15.1M 15.7M — —
↳ 5y CAGR +10.6% +9.8% +34.7% +37.8% +17.9% +27.9% +30.1% +15.3%
Total comprehensive income (USD) -11.6M -9.72M -16.6M -19M -10.1M -22.3M -31M -30.3M -16.7M -15.4M
Comprehensive income to owners (USD) -11.6M -9.72M -16.6M -19M -10.1M -22.3M -31M -30.3M -16.7M -15.4M
Provision for credit losses (USD) 65,378 904 14,762 72,429 -102,310 -512 -8,354 14,434 115,161 40,000
Credit cost ratio (credit losses / average receivables) (%) 6.3% 0.0% 0.5% 1.7% 2.1% 0.0% 0.2% 0.2% 1.7% 0.5%
Reported Mar 3, 2017 Mar 7, 2019 May 7, 2019 Mar 5, 2020 Mar 9, 2021 Mar 10, 2022 Mar 9, 2023 Mar 15, 2024 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

PRINCETON, N.J., November 12, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory update.

Third Quarter 2026 Financial Results

• Revenue was $9.7 million, an increase of 3% compared to $9.5 million in Q3 2025. Growth was led by a 16% increase in distributor and strategic partner sales.

• Gross margin improved to 75% in the quarter, up from 73% in Q2 2026 and 70% a year ago.

• Total operating expenses decreased 11% to $8.5 million from $9.5 million in Q3 2025. Excluding $0.25 million of restructuring charges, operating expenses decreased 13%.

• Operating loss improved by 59% to $1.2 million versus $2.9 million in Q3 2025.

• Net loss improved by 42% to $1.8 million or $0.58 per share, compared to a net loss of $3.2 million or $1.01 per share in Q3 2025. All per share amounts reflect the 1-for-20 reverse stock split effected on September 8, 2026.

PRINCETON, N.J., Oct. 29, 2026 /PRNewswire/ — CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2026 financial results and recent business highlights after the market close on Thursday, November 12, 2026.

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)

CytoSorbents’ management will host a live presentation webcast and a question-and-answer session starting at 4:30PM ET the same day. 

**Webcast Details:**Date: Thursday, November 12th, 2026Time: 4:30 PM ETLive webcast link: https://app.webinar.net/QGnj7PY3lZV

It is recommended that participants join the webcast approximately 10 minutes prior to the start of the call.

An archived recording of the conference call will be available under the Investor Relations section of the Company’s website at https://ir.cytosorbents.com/ .

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation  is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents’ lead product, CytoSorb ® , is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor  and rivaroxaban  removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization  in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations : one for the removal of ticagrelor  and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban  in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®, ContrastSorb, PuriFi®, HotSwap™ and others.

PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October 7-10, 2026 and in critical care at the European Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon, Portugal from October 10-14, 2026. 

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents’ flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is seeking U.S. FDA and Health Canada marketing approval of DrugSorb™-ATR for antithrombotic drug removal during cardiothoracic surgery. (PRNewsfoto/CytoSorbents Corporation)

Upcoming International EACTS and ESICM Conferences Highlight CytoSorb Use in Cardiac Surgery and Critical Care

 is the world’s largest cardiothoracic surgery conference, focusing on advancements, innovations, and surgical techniques for heart and lung conditions.  The following data presentations highlight the use of CytoSorb in cardiac surgery:

Thursday, October 8, 2026:

  • Intraoperative Hemoadsorption to Reduce Bleeding in Isolated CABG under Dual P2Y12 Inhibitor and DOAC Therapy Prof. Michael Schmoeckel (Ludwig Maximilian University (LMU), Munich, Germany)

  • Hemoadsorption for Postoperative Vasoplegia: Real-World Data from the International Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry. Prof. Federico Papallardo (San Raffaele University, Milan, Italy)

  • Hemoadsorption to Reduce Hyperinflammation during VA-ECMO: Results from the International Prospective COSMOS Registry. Prof. Federico Papallardo (San Raffaele University, Milan, Italy)

Friday, October 9, 2026:

  • Improved short– and long–term outcomes in ‘high–risk’ heart transplant patients with adjunctive intraoperative hemoadsorption treatment – A single centre’s decade of experience Prof. Endre Nemeth (Heart and Vascular Centre, Semmelweis University, Budapest, Hungary)

ESICM LIVES 2026

 is one of the leading international critical care conferences highlighting the latest research, guidelines, and treatments in intensive care medicine.  Data from the COSMOS Registry will be presented by Prof. Ricard Ferrer (Vall d’Hebron Hospital, Barcelona, Spain).

Monday, October 12, 2026

  • Liver Support with Hemoadsorption: Initial Report from the International, Prospective COSMOS Registry

  • Hemoadsorption to Treat Hyperinflammation During VV-ECMO: Preliminary Report from the International COSMOS Registry.

Tuesday, October 13, 2026

  • Hemoadsorption for Postoperative Vasoplegia: An Analysis from the International, Prospective COSMOS Registry.

  • CytoSorb hemoadsorption as an adjunctive treatment in sepsis and septic shock: Insights from the first 200 patients included in the international, prospective COSMOS Registry.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, “We are pleased to see such a broad body of clinical data on CytoSorb accepted for presentation at two of the world’s leading cardiac surgery and critical care conferences.  These presentations span important areas of unmet medical need across cardiac surgery – including the removal of blood thinners, heart transplantation, heart failure, and shock following open heart surgery – as well as critical care applications such as acute liver disease, acute respiratory distress syndrome (ARDS), and septic shock.  The latter is particularly timely as Sepsis Awareness Month draws to a close and reinforces the continued need for more powerful approaches like CytoSorb to help manage the life-threatening hyperinflammation and organ dysfunction associated with this devastating condition.”

Dr. Chan concluded, “We remain deeply committed to supporting high-quality clinical research and expanding the evidence base for CytoSorb across a wide range of deadly conditions.  A cornerstone of this effort is our international, prospective, multicenter COSMOS Registry, which is designed to systematically capture real-world clinical experience with CytoSorb across a broad spectrum of critically ill patients.  By generating data on how CytoSorb is being used in everyday clinical practice – including patient selection, timing and duration of therapy, safety, and clinical outcomes – COSMOS is providing important insights that complement controlled clinical studies, help clinicians further refine and optimize CytoSorb therapy, and help to further establish the role of CytoSorb in the management of complex cardiac surgery and critical care patients worldwide.  We are excited to see this growing body of evidence being shared with the international medical community.”

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation

 is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents’ lead product, CytoSorb

®

, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date.  CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber.  Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor

 and rivaroxaban

 removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization

 in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure.  CytoSorb is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs.  It has received two FDA Breakthrough Device Designations

:  one for the removal of ticagrelor

 and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban

 in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery.  The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA.  DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit the Company’s website at https://ir.cytosorbents.com/

  or follow us on Facebook

 and X

. 

Prompts

Cytosorbents Corporation (ticker CTSO), listed in United States.

Company History

Date Change Detail
May 7, 2010 Renamed MedaSorb Technologies CORP → CYTOSORBENTS CORP
Aug 7, 2006 Renamed GILDER ENTERPRISES INC → MedaSorb Technologies CORP

ETFs Holding Cytosorbents Corporation

ETF Weight in ETF Shares Market value As of
MSSM 0.00% 20,476 $ 6,982.32 Aug 31, 2026